News
Verastem Oncology Cancer Drug Combination Gets FDA Approval
Verastem Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ovarian cancer. The company expects a combination co-pack will be available in the U.S. in about a week.
Verastem scores FDA nod for first-of-its-kind oral combination to treat rare form of ovarian cancer
In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination treatment of avutometinib and defactinib for a rare form of ovarian cancer. | Verastem Oncology has gained its first FDA approval,
1 in 4 women in the U.S. between ages 45 and 60 are at high risk for breast cancer; a new drug combination, bazedoxifene and conjugated estrogens, not only reduced breast cancer risk—but also ...
Approximately 25% of women in the United States between ages 45 and 60 are at high risk for breast cancer and should ... in women who are taking the drug combination," Giles said.
The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback